-
公开(公告)号：US12121536B2
公开(公告)日：2024-10-22
申请号：US17646805
申请日：2022-01-03
申请人： Galleon Labs LLC
发明人： Gary S. Hahn , Siva Gudi
IPC分类号： A61K33/00 , A61K9/00 , A61K31/19 , A61K31/198 , A61K31/22 , A61K33/14 , A61K47/32 , A61K47/54 , A61K31/455 , A61K33/18 , A61K33/38 , A61K45/06
CPC分类号： A61K33/00 , A61K9/0014 , A61K31/19 , A61K31/198 , A61K31/22 , A61K33/14 , A61K47/32 , A61K47/542 , A61K9/0053 , A61K31/455 , A61K33/18 , A61K33/38 , A61K45/06 , A61K33/14 , A61K2300/00 , A61K31/22 , A61K2300/00 , A61K31/198 , A61K2300/00
摘要： Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.
-
公开(公告)号：US12071673B2
公开(公告)日：2024-08-27
申请号：US16694845
申请日：2019-11-25
发明人： Mark Pimentel , Ruchi Mathur , Christopher Chang
IPC分类号： C12Q1/689 , A61K31/137 , A61K31/155 , A61K31/22 , A61K31/337 , A61K31/351 , A61K31/357 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/4164 , A61K31/437 , A61K31/454 , A61K31/47 , A61K31/505 , A61K31/55 , A61K31/7036 , A61K31/7048 , A61K35/741 , A61K45/06
CPC分类号： C12Q1/689 , A61K31/137 , A61K31/155 , A61K31/22 , A61K31/337 , A61K31/351 , A61K31/357 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/4164 , A61K31/437 , A61K31/454 , A61K31/47 , A61K31/505 , A61K31/55 , A61K31/7036 , A61K31/7048 , A61K35/741 , A61K45/06 , C12Q2600/106 , A61K35/741 , A61K2300/00 , A61K31/155 , A61K2300/00 , A61K31/437 , A61K2300/00 , A61K31/7036 , A61K2300/00 , A61K31/4164 , A61K2300/00 , A61K31/40 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/366 , A61K2300/00 , A61K31/47 , A61K2300/00 , A61K31/22 , A61K2300/00 , A61K31/505 , A61K2300/00 , A61K31/137 , A61K2300/00 , A61K31/7048 , A61K2300/00 , A61K31/454 , A61K2300/00
摘要： The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
-
公开(公告)号：US20240216461A1
公开(公告)日：2024-07-04
申请号：US17567892
申请日：2022-01-04
申请人： Peter Nguyen
发明人： Peter Nguyen
IPC分类号： A61K36/63 , A61K9/00 , A61K31/122 , A61K31/22 , A61K31/593 , A61K35/644 , A61K36/28 , A61K36/48 , A61K36/53 , A61K36/61 , A61K36/889
CPC分类号： A61K36/63 , A61K9/0053 , A61K31/122 , A61K31/22 , A61K31/593 , A61K35/644 , A61K36/28 , A61K36/48 , A61K36/53 , A61K36/61 , A61K36/889
摘要： In summary, the present disclosure is directed to a soft gel food supplement; formulated in eleven natural antiviral ingredients; to boost the immune system. The present disclosure contains natural antiviral antibacterial ingredients that makes the human immune system a more complex network of cells and proteins that defends the body against infection. The immune system keeps a record of every germ (microbe) it has ever defeated so it can recognize and destroy the microbe quickly if it enters the body again.
Covid will attack everybody in its path. However, when a variant attempts to infect those who use the present disclosure dietary supplement formula and method, the immune system is nourished and ready to boost its normal function to the utmost in recognizing and destroying the virus and its variants efficiently.-
公开(公告)号：US20240216320A1
公开(公告)日：2024-07-04
申请号：US18605474
申请日：2024-03-14
申请人： Augusta University Research Institute, Inc. , Bar Ilan University , Ramot at Tel-Aviv University Ltd.
发明人： Betty S. PACE , Abraham NUDELMAN , Zvi MALIK , Ada REPHAELI
CPC分类号： A61K31/22 , A61K9/0048 , A61K9/0053 , A61K31/17 , A61P7/06
摘要： It has been found that the prodrug 1-(butyryloxy)ethyl-5-amino-4-oxopentanoate (AN-233), an oral active conjugate of BA (histone deacetylase inhibitor) and ALA (heme precursor), is useful for the treatment of hemoglobinopathies including but not limited to sickle cell disease and thalassemias. In one embodiment, AN-233 activates γ-globin transcription, induces HbF expression, produces an anti-sickling effect, or combinations thereof when administered to a subject in need thereof.
-
公开(公告)号：US20240180864A1
公开(公告)日：2024-06-06
申请号：US18539960
申请日：2023-12-14
CPC分类号： A61K31/22 , A61K9/14 , A61K9/1676 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5078 , A61K9/5084 , A61K31/19
摘要： Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
-
公开(公告)号：US20240156795A1
公开(公告)日：2024-05-16
申请号：US18550919
申请日：2022-03-17
IPC分类号： A61K31/4418 , A61K9/00 , A61K31/155 , A61K31/22 , A61K31/405 , A61K31/4178 , A61K33/18 , A61K47/14 , A61K47/20 , A61P17/00 , A61P31/10
CPC分类号： A61K31/4418 , A61K9/0014 , A61K31/155 , A61K31/22 , A61K31/405 , A61K31/4178 , A61K33/18 , A61K47/14 , A61K47/20 , A61P17/00 , A61P31/10
摘要： Compositions and methods for the treatment of topical infections such as onychomycosis are disclosed.
-
公开(公告)号：US20240156760A1
公开(公告)日：2024-05-16
申请号：US18414988
申请日：2024-01-17
申请人： BASF AS
发明人： Hilde STEINEGER , David Alan FRASER , Tore SKJÆRET
摘要： The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II):
wherein R1, R2, R3, X and Y are as defined in the specification;
or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I):
wherein R2, R3, and X, are as defined in the specification;
or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R2, R3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.-
公开(公告)号：US11911354B2
公开(公告)日：2024-02-27
申请号：US17551673
申请日：2021-12-15
申请人： BASF AS
发明人： Hilde Steineger , David Alan Fraser , Tore Skjæret
IPC分类号： A61K31/10 , C07C321/18 , A61K31/19 , A61K31/22 , A61P1/16
摘要： The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II):
wherein R1, R2, R3, X and Y are as defined in the specification;
or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I):
wherein R2, R3, and X, are as defined in the specification;
or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.
Further, the present invention relates to a compound of Formula (I) for preventing and/or treating non-alcoholic steatohepatitis, wherein R2, R3 and X are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.-
公开(公告)号：US20240058409A1
公开(公告)日：2024-02-22
申请号：US18453497
申请日：2023-08-22
IPC分类号： A61K36/324 , A61K31/22 , A61K35/745 , A61P11/06 , A61P37/08
CPC分类号： A61K36/324 , A61K31/22 , A61K35/745 , A61P11/06 , A61P37/08
摘要： A gut microbiome may be modulated in a patient in need thereof, by administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient; wherein the composition is administered at a dose sufficient to change the ratio between a first organism in the gut microbiome and a second organism in the gut microbiome, compared to a subject not treated with the composition. Modulation of the gut microbiome with AKBA may be used to treat allergic pulmonary inflammation in the patient. Modulation of the gut microbiome with AKBA may be used to maintain diversity and/or increase a percentage of Bifidobacterium pseudolongum in the gut microbiome of the patient. The composition may further comprise a lyophilized probiotic bacteria. The composition may be administered in combination with a second composition comprising a lyophilized probiotic bacteria.
-
10.发明公开公开(公告)号：US20240058292A1
公开(公告)日：2024-02-22
申请号：US18259402
申请日：2021-12-31
申请人： Yaqin DENG
发明人： Yaqin DENG
IPC分类号： A61K31/22 , A61K31/045 , A61K31/10 , A61K31/121 , A61P35/00
CPC分类号： A61K31/22 , A61K31/045 , A61K31/10 , A61K31/121 , A61P35/00
摘要： Clean version of the Abstract A pharmaceutical composition for treating cancer, and a preparation method and use thereof are provided. The pharmaceutical composition includes an ester compound and dimethylsulfoxide (DMSO), a ketone compound and DMSO, or an alcohol compound and DMSO. The pharmaceutical composition is of a great value for a prevention and a treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
3670 条记录 (耗时 0.04 秒)
